ARS Pharma Submits Response For Neffy MAA To EMA's CHMP, Signs License Deal With CSL Seqirus

ARS Pharmaceuticals (SPRY), Tuesday announced the submission of Day 180 response for Neffy's Marketing Authorization Application to the Committee for Medicinal Products for Human Use of the European Medicines Agency, expecting to receive the opinion on the drug in the second quarter of 2024.

Related Keywords

New Zealand ,Australia , ,Committee For Medicinal Products Human Use ,Nasdaq ,Marketing Authorization Application ,Medicinal Products ,Human Use ,European Medicines Agency ,Ars Pharma Deal With Csl Seqirus ,Effy Drug For Allergic Reactions ,Rs Pharma Allergic Drug ,